Literature DB >> 17998831

Resistin is an inflammatory marker of inflammatory bowel disease in humans.

Astrid Konrad1, Michael Lehrke, Veronika Schachinger, Frank Seibold, Renee Stark, Thomas Ochsenkühn, Klaus G Parhofer, Burkhard Göke, Uli C Broedl.   

Abstract

OBJECTIVES: Resistin, a recently discovered adipokine, has been shown to be associated with inflammatory conditions such as insulin resistance, obesity, atherosclerosis and rheumatoid arthritis. We therefore hypothesized that (i) resistin levels may be elevated in patients with inflammatory bowel disease (IBD) and (ii) resistin levels may be associated with disease activity in IBD.
METHODS: We addressed these questions by testing for associations between resistin plasma levels, inflammatory parameters and clinical disease activity in a case-control study with 235 patients with Crohn's disease (CD), 112 patients with ulcerative colitis (UC) and 144 healthy controls.
RESULTS: Patients with IBD showed significantly higher resistin levels compared with controls (P<0.0001). In both, patients with CD and UC, resistin concentrations were significantly associated with elevated white blood cell count (P<0.0001), C-reactive protein (CRP) (P<0.0001) and disease activity (P< or =0.0001). In multivariate logistic regression analysis, resistin levels were identified as an independent predictor of active disease (odds ratio 1.014, 95% confidence interval 1.002-1.027, P=0.02) in patients with CD after adjusting for sex, age, body mass index, white blood cell count and CRP. In UC patients, resistin was associated with active disease in multivariate regression analysis after control for sex, age, body mass index and white blood cell count (odds ratio 1.015, 95% confidence interval 1.002-1.029, P=0.02). Addition of CRP, however, abolished this association.
CONCLUSION: Resistin levels are an independent predictor of disease activity in patients with CD. Resistin may represent a novel link between inflammation and IBD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998831     DOI: 10.1097/MEG.0b013e3282f16251

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  55 in total

1.  The effect of body weight on the severity and clinical course of ulcerative colitis.

Authors:  Denia Stabroth-Akil; Ludger Leifeld; Roland Pfützer; Julia Morgenstern; Wolfgang Kruis
Journal:  Int J Colorectal Dis       Date:  2014-11-14       Impact factor: 2.571

Review 2.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

3.  Does plasma resistin level have a role in predicting inflammatory bowel disease activity?

Authors:  N A Abdel Kader; F A Ali El-Din; E A A Khatab; N E ELAbd
Journal:  Indian J Gastroenterol       Date:  2010-06

Review 4.  Adipokines and insulin resistance.

Authors:  Katja Rabe; Michael Lehrke; Klaus G Parhofer; Uli C Broedl
Journal:  Mol Med       Date:  2008-09-17       Impact factor: 6.354

Review 5.  Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews.

Authors:  Nava Morshedzadeh; Mehran Rahimlou; Hamid Asadzadeh Aghdaei; Shabnam Shahrokh; Mohammad Reza Zali; Parvin Mirmiran
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

6.  Obesity Is Associated with Increased Risk of Colectomy in Inflammatory Bowel Disease Patients Hospitalized with Clostridium difficile Infection.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Dig Dis Sci       Date:  2018-12-19       Impact factor: 3.199

Review 7.  Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis.

Authors:  Laura J Dixon; Amrita Kabi; Kourtney P Nickerson; Christine McDonald
Journal:  Inflamm Bowel Dis       Date:  2015-04       Impact factor: 5.325

8.  A new model for the discrimination between ulcerative colitis and Crohn's disease.

Authors:  Zhe Shen; Wei-Ping Ma; Xiao-Na Shao; Chao-Hui Yu; Juan Du; Zun Xiang; Gan-Hua Guo; Hong Zhang; You-Ming Li; Min Yue
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 9.  Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Authors:  Siddharth Singh; Parambir S Dulai; Amir Zarrinpar; Sonia Ramamoorthy; William J Sandborn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

10.  Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway.

Authors:  Jian Zhang; Ting Lei; Xiaodong Chen; Yin Peng; Huan Long; Lei Zhou; Jianfeng Huang; Zhilong Chen; Qinqiang Long; Zaiqing Yang
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.